RxDoctor Payments Data

Lisa Wydra

Family · Brick, NJNPI 1780916916

Payments from drug & device makers

$1,610in general payments, 2019–2025

Across 93 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$272
  • GSK$265
  • Sanofi$176
  • Takeda Pharmaceuticals U.S.A., Inc.$161
  • CSL Behring$103
  • Amgen$101
  • plus $533 from 16 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$1,59099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,610 in reported general payments places this provider in the 80th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$120,087
Medicare patients
178
Services billed
4,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,327
Epinephrine15$3,613
SymbicortBudesonide/Formoterol Fumarate14$3,231
Fluticasone Propionate74$1,438
Albuterol Sulfate HfaAlbuterol Sulfate45$1,379
Azelastine Hcl38$971
Ipratropium Bromide20$632
Levocetirizine Dihydrochloride28$377
Montelukast Sodium20$147
Prednisone19$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$265$8,32711 claims
AstraZenecaSymbicort$272$3,23114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,692 family providers in New Jersey.

Other family in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →